Health Concerns About Weight Loss Injections: Making an Informed Decision

Are these concerns about short-term side effects or longer-term unknowns?

Most people asking about health concerns are actually asking two different questions at once. One is about the side effects that show up in the first weeks of treatment. The other is about what happens over years of use in a much broader population than any clinical trial can capture. It is worth separating them.

Short-term effects are well-documented. Nausea is the most frequently reported, with vomiting, diarrhoea and constipation appearing in trials at varying rates depending on the medicine and dose. These symptoms are concentrated around the early stages of treatment and often settle as the body adjusts. The NHS medicines page for tirzepatide lists the full common-side-effect profile, and it is readable, not alarming.

Longer-term data are thinner, as they always are with medicines licensed in the last decade. Both Mounjaro and Wegovy carry a Black Triangle designation in the UK, which does not mean they are dangerous, it means the MHRA is actively collecting additional post-market data to build a fuller picture. That is standard for newer medicines and is, if anything, a sign that the regulatory system is working. What is clear is that for people with obesity-related health conditions, the clinical evidence of benefit (including cardiovascular outcomes in semaglutide's STEP trials) has been strong enough for NICE to recommend both medicines within defined NHS criteria. Whether the benefit outweighs the risk for you personally is a clinical judgement, not a general one. Our clinical team works through exactly this kind of reasoning with every patient.

Which health concerns specifically lead prescribers to say no?

A prescriber assessing your suitability is not just looking at your BMI. They are looking at your full medical history for contraindications, conditions where these medicines should not be used or require very careful thought.

A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) is a contraindication for both medicines. A history of pancreatitis warrants careful discussion, given that acute pancreatitis is a known associated risk. Severe gastrointestinal disease (gastroparesis, for example) may make the gastric-slowing mechanism of these medicines problematic rather than helpful. Eating disorder history is not an automatic exclusion, but it does require an honest conversation; if that is relevant to you, the relationship between weight loss injections and mental health is a topic we have covered separately.

Kidney function matters too: severe dehydration from prolonged vomiting or diarrhoea can put stress on the kidneys, so someone with pre-existing impairment needs closer monitoring. The prescriber also asks about your current medicines. Women taking oral contraceptives and starting tirzepatide should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because the absorption of the pill may be reduced, something NHS England's weight-management guidance flags explicitly.

None of this is hidden information. It is precisely why these are prescription-only medicines: a prescriber who has reviewed your history and current medications is far better placed to weigh these considerations than any general-interest article, including this one. You can explore whether weight loss injections are healthy overall in a broader piece we have put together on the topic.

Pancreatitis, thyroid risk and the serious-but-rare end of the spectrum

Some health concerns that circulate online sit at the serious end of the risk spectrum, and they deserve a straight answer rather than reassurance by omission.

Pancreatitis is the one the MHRA has been most direct about. In January 2026 it published a Drug Safety Update specifically addressing GLP-1 medicines and acute pancreatitis, confirming it as a known risk and advising patients to seek urgent medical attention for severe, persistent stomach pain that may radiate towards the back, with or without vomiting. Infrequent does not mean impossible, and knowing the warning sign matters. You can report suspected side effects and check safety communications at the MHRA's Yellow Card scheme.

Thyroid cancer concerns arise partly from rodent studies in which very high GLP-1 receptor stimulation was associated with thyroid C-cell changes. These findings have not translated into a demonstrated increased risk in humans at therapeutic doses, but the contraindication for people with a personal or family history of MEN2 or medullary thyroid carcinoma remains in place. That is a precautionary measure based on mechanism, not confirmed human cases.

Gallbladder problems (including gallstones) appear more frequently in people losing significant amounts of weight by any method, and GLP-1 medicines are no exception. Rapid weight reduction is itself a risk factor. The documented health benefits of these treatments need to be read alongside this context, which is why clinical oversight matters for the duration of treatment, not just at the start.

How to weigh the health concerns against the health cost of untreated obesity

This is the question that often gets lost in conversations about side-effect risk. Obesity is not a neutral baseline. It is associated with type 2 diabetes, hypertension, obstructive sleep apnoea, cardiovascular disease, joint damage and several cancers. These are not theoretical risks; they are the conditions that shortened life expectancy for millions of people in the UK. The medicines licensed for weight management were developed and assessed in that context.

NICE's recommendation of tirzepatide (TA1026) and semaglutide (TA875) was made after weighing the clinical evidence on both sides: what the medicines do for health outcomes, and what harms they carry. That process concluded that for eligible patients the balance is favourable. It does not follow that everyone above the BMI threshold should take them. It means the case for treatment is strong enough to justify it within a proper clinical framework.

If you are on the fence, the most useful thing you can do is have that conversation with a prescriber who can look at your specific picture. People sometimes order on a Monday after payday, thinking they have already decided, but the consultation itself often surfaces something useful, a question not thought of, a medication interaction worth knowing about, or simply confirmation that the risks are manageable for them specifically. For a broader sense of what the weight loss treatment landscape looks like, that page is a useful starting point. If you are comparing services and want to know how providers such as Nuffield Health approach these treatments, we have put together a dedicated guide on Nuffield Health weight loss injections that is worth reading alongside your research. And if you want to understand what a clinically supervised service looks like in practice, you can read more about how we work. When you are ready to have that conversation properly, start your free consultation and a GPhC-registered prescriber will review your case the same day, and our guide to the healthiest weight loss injections can help you go into that conversation feeling better informed.